KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Novavax (NVAX) Equity Ratio (2016 - 2025)

Historic Equity Ratio for Novavax (NVAX) over the last 17 years, with Q3 2025 value amounting to 0.13.

  • Novavax's Equity Ratio rose 5680.53% to 0.13 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.13, marking a year-over-year increase of 5680.53%. This contributed to the annual value of 0.4 for FY2024, which is 23.62% down from last year.
  • According to the latest figures from Q3 2025, Novavax's Equity Ratio is 0.13, which was up 5680.53% from 0.03 recorded in Q2 2025.
  • Novavax's Equity Ratio's 5-year high stood at 0.4 during Q1 2021, with a 5-year trough of 0.64 in Q1 2024.
  • In the last 5 years, Novavax's Equity Ratio had a median value of 0.24 in 2024 and averaged 0.19.
  • Its Equity Ratio has fluctuated over the past 5 years, first skyrocketed by 64522.76% in 2021, then tumbled by 261933.14% in 2023.
  • Quarter analysis of 5 years shows Novavax's Equity Ratio stood at 0.14 in 2021, then crashed by 105.69% to 0.28 in 2022, then plummeted by 42.08% to 0.4 in 2023, then fell by 0.24% to 0.4 in 2024, then surged by 66.79% to 0.13 in 2025.
  • Its Equity Ratio stands at 0.13 for Q3 2025, versus 0.03 for Q2 2025 and 0.06 for Q1 2025.